DNA Vaccine for Ragweed Allergic Adults

Completed · Phase 2

Conditions studied: Seasonal Allergic Rhinitis

In brief

Various chemical modifications of allergens have been attempted to enhance efficacy, improve safety, and foster compliance with IT. These approaches have been unsuccessful - in that the allergenicity and immunogenicity have either decreased, or increased in tandem, with no resultant efficacy: safety benefit ratio. This study utilizes an adjuvant approach in which synthetic immunostimulatory DNA is conjugated to ragweed allergen in an attempt to modulate both the clinical and immunologic allergic response to ragweed exposure in ragweed-allergic patients with seasonal rhinitis.

Key facts

Study ID

NCT00346086

Run by

Johns Hopkins University

People needed

25

Starts

2001-05-18

Expected to finish

2001-08-21

Last updated by the study team

2018-12-13

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult men and women 18 to 60 years of age;
• Who provide informed consent;
• Have a history of fall, seasonal, allergic rhinitis consistent with ragweed allergy;
• Exhibit a positive skin test to licensed , standardized, ragweed extract and a positive acute response to ragweed nasal challenge;
• Are in general good health; and are available for the duration of the study.

You may not qualify if…

• Individuals with medical conditions or taking medications that might interfere with interpretation of the study results will be excluded.
• Those with a history of severe symptoms of allergic rhinitis during the spring and summer grass pollen season will be excluded.

Where it is running

• Johns Hopkins University School of Medicine — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.